Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 33,300 shares, a decrease of 18.0% from the September 15th total of 40,600 shares. Based on an average trading volume of 9,500 shares, the days-to-cover ratio is currently 3.5 days.
Nanobiotix Trading Down 0.2 %
Shares of NASDAQ:NBTX opened at $4.95 on Monday. The firm’s 50 day simple moving average is $5.12 and its 200 day simple moving average is $5.60. Nanobiotix has a fifty-two week low of $4.14 and a fifty-two week high of $8.96.
Analyst Ratings Changes
Separately, Guggenheim initiated coverage on shares of Nanobiotix in a research note on Wednesday, August 28th. They issued a “buy” rating and a $12.00 target price on the stock.
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- How to Invest in Small Cap Stocks
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Breakout Stocks: What They Are and How to Identify Them
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- 10 Best Airline Stocks to Buy
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
